Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of Income from Continuing Operations readings, the most recent being 17744000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations rose 273.98% to 17744000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 71751000.0 through Dec 2025, up 475.6% year-over-year, with the annual reading at 71751000.0 for FY2025, 475.6% up from the prior year.
  • Income from Continuing Operations hit 17744000.0 in Q4 2025 for Oramed Pharmaceuticals, down from 48389000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 48389000.0 in Q3 2025 and bottomed at 22989000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 531000.0, with a median of 5208000.0 recorded in 2023.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 800.99% in 2024 before it crashed 598.17% in 2025.
  • Oramed Pharmaceuticals' Income from Continuing Operations stood at 22989000.0 in 2021, then surged by 46.69% to 12255000.0 in 2022, then soared by 208.49% to 13296000.0 in 2023, then plummeted by 176.71% to 10199000.0 in 2024, then soared by 273.98% to 17744000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Income from Continuing Operations are 17744000.0 (Q4 2025), 48389000.0 (Q3 2025), and 13260000.0 (Q2 2025).